Drug Trial Radar · NCT07548177
Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
33
Planned (sponsor's estimate)
Start
Apr 2, 2026
Primary completion
Dec 2028
Study completion Jun 2029
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, single-arm, multicenter clinical study aimed at demonstrating the effectiveness of benmelstobart injection combined with anlotinib hydrochloride capsules in patients aged 14 years or older with advanced or unresectable alveolar soft part sarcoma by evaluating the objective response rate (IRC).
Conditions
- Alveolar Soft Part Sarcoma
Interventions
Benmelstobart injection combined with Anlotinib hydrochloride capsuleDrug
Benmelstobart is a PD-L1 immunosuppressant. Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (IRC assessment)Time frame: The period from baseline to the end of the trial is expected to be 32 months.
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Army Medical University of the People's Liberation Army of China
Chongqing, Chongqing Municipality, China · Not yet recruiting
Sun Yat-sen University Cancer Center
Guangdong, Guangdong, China · Not yet recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Not yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Xiangya Hospital of Central South University
Changsha, Hunan, China · Not yet recruiting
The first hospital of Jilin University
Changchun, Jilin, China · Not yet recruiting
Shandong First Medical University Affiliated Tumor Hospital
Jinan, Shandong, China · Not yet recruiting
Shanghai General Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Not yet recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Xinjiang Medical University Affiliated Cancer Hospital
Ürümqi, Xinjiang, China · Not yet recruiting
The Second Affiliated Hospital, Zhejiang University School of Medicine.
Hangzhou, Zhejiang, China · Not yet recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.